FDA
-
-
-
-
-
-
-
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene raises over $28 million in registered direct offering
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene (CLNN) Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment
-
-
-
-
-
-
-
Clene, Inc. (CLNN) PT Lowered to $84 at Benchmark
-
-
-
-
-
-
-
Clene (CLNN) Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
-
330,678 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

